Trial Profile
A randomized, double-blind, multi-centre to evaluate the efficacy and safety of adding mirabegron to solifenacin in incontinent OAB subjects requiring additional relief for their OAB symptoms (The BESIDE Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Solifenacin
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms The BESIDE Study
- 29 Aug 2014 Status changed from recruiting to active, no longer recruiting as compared by ClinicalTrials.gov record.
- 23 Aug 2013 New trial record